Background: Skeletal Class III patients can be treated with bone anchored maxillary protraction (BAMP) treatment. The placement of miniplates is an invasive operation and needs to be carried out under general anesthesia.
Aim: The aim of this retrospective study was to determine the failure rate of miniplates.
Methods: All the patients who had miniplates placed for BAMP treatment between January 2010 and April 2020 in Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, Finland were included in this study. The patient records were retrospectively screened. The success rate of the placement of orthodontic miniplates was evaluated between surgical residents (Group 1) and consultant surgeons (Group 2).
Materials: The study group consisted of 164 miniplates in 42 patients. The miniplates were divided into two groups, depending on the placement operator. Group 1 consisted of 86 miniplates placed by surgical residents. Group 2 consisted of 78 miniplates placed by consultant surgeons.
Results: In Group 1 (11 females, 14 males) and Group 2 (16 females, 9 males). The overall failure rate of miniplates was 23.8% (n = 39). The failure rate for surgical residents (Group 1) was 31.4% (n = 27) and for consultant surgeons (Group 2), 15.3% (n = 12) (p < 0.05). Out of all the failed miniplates 69.2% (n = 27) were placed by residents and 30.8% (n = 12) by consultants.
Limitations: This retrospective study consisted of a limited number of patients.
Conclusion: The failure rate of miniplates placed by consultant surgeons was lower compared to surgical residents (p < 0.05).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2340/aos.v84.43123 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Merkel cell carcinoma: An update].
Bull Cancer
March 2025
Dermatologie, CHU de Tours, Tours, France; Réseau CARADERM, France.
Merkel cell carcinoma (MCC) is a rare skin cancer that mainly affects the elderly, and whose incidence is increasing. Although the exact origin of this cancer remains uncertain, research in recent years has revealed that MCC develops through two oncogenesis pathways: virally induced by the Merkel polyomavirus (80% of cases) and induced by mutations linked to ultraviolet rays (20% of cases). MCC is an aggressive cancer, with a high mortality rate and limited therapeutic options in advanced stage.
View Article and Find Full Text PDFAtrial fibrillation development in the heart failure population from nationwide British linked electronic health records.
ESC Heart Fail
March 2025
Institute of Health Informatics Research, University College London, London, UK.
Aims: Atrial fibrillation (AF) is a frequent comorbidity in heart failure (HF). We analysed factors associated with new-onset atrial fibrillation in patients with heart failure using linked real-world UK data from primary and secondary care, along with findings from genome-wide association studies.
Methods And Results: Among 163 174 participants with a diagnosis of HF (January 1998 to May 2016) from Clinical Practice Research Datalink (CPRD) and Hospital Episodes Statistics (HES), 111 595 participants had no previous history of AF (mean age 76.
Cytokine therapy of acute radiation syndrome.
Best Pract Res Clin Haematol
December 2024
Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, SW7 2AZ, UK.
Radiological accidents/incidents are common with nearly 400 reported since 1944 exposing about 3000 people to substantial doses of ionizing radiations with 127 deaths. Damage to hematopoietic stem and progenitor cells with resulting bone marrow failure is a common consequence of exposure to whole body acute high-dose and -dose-rate ionizing radiations and is termed hematopoietic-acute radiation syndrome, or H-ARS. Therapy of H-ARS includes transfusions, anti-bacterial and -viral drugs, molecularly-cloned hematopoietic growth factors and hematopoietic cell transplants.
View Article and Find Full Text PDFEfficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy.
J Am Coll Cardiol
March 2025
National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed chronic disease associated with progressive heart failure that results in impaired quality of life, repeated hospitalizations, and premature death. Acoramidis is a selective, oral transthyretin stabilizer recently approved by the U.S.
View Article and Find Full Text PDFInvestigation of the Effect of Empagliflozin on Cardiac Sympathetic and Parasympathetic Nerve Activity Analyzed From Heart Rate Variability Frequency in Japanese Patients With Type 2 Diabetes - Results From the EMPYREAN Study.
Circ J
March 2025
Department of Cardiovascular Medicine, Shinshu University School of Medicine.
Background: The EMPA-REG OUTCOME trial confirmed empagliflozin reduced mortality and heart failure hospitalization risk. These findings raised the possibility that empagliflozin may modulate cardiac autonomic function in patients with type 2 diabetes (T2D).
Methods And Results: The EMPYREAN study was a prospective randomized open-label assessor-blinded multicenter investigation of patients with T2D without prior antidiabetic therapy with sodium-glucose cotransporter 2 or dipeptidyl peptidase 4 inhibitors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!